Fu‐Fei Hsu

1.4k total citations
15 papers, 636 citations indexed

About

Fu‐Fei Hsu is a scholar working on Molecular Biology, Immunology and Infectious Diseases. According to data from OpenAlex, Fu‐Fei Hsu has authored 15 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Immunology and 4 papers in Infectious Diseases. Recurrent topics in Fu‐Fei Hsu's work include SARS-CoV-2 and COVID-19 Research (4 papers), Phagocytosis and Immune Regulation (3 papers) and Viral gastroenteritis research and epidemiology (2 papers). Fu‐Fei Hsu is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (4 papers), Phagocytosis and Immune Regulation (3 papers) and Viral gastroenteritis research and epidemiology (2 papers). Fu‐Fei Hsu collaborates with scholars based in Taiwan, United States and Singapore. Fu‐Fei Hsu's co-authors include Yunching Chen, Yun‐Chieh Sung, Hsi‐Chien Huang, Yi-Hung Ou, Sheau-Yann Shieh, Kuan‐Wei Huang, Han‐Chung Wu, Jian‐Tai Qiu, Chu-Chi Lin and Yu‐Ting Huang and has published in prestigious journals such as The EMBO Journal, Advanced Functional Materials and Hepatology.

In The Last Decade

Fu‐Fei Hsu

15 papers receiving 632 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fu‐Fei Hsu Taiwan	11	316	161	117	113	87	15	636
Michaela Jeong South Korea	8	656 2.1×	121 0.8×	75 0.6×	65 0.6×	80 0.9×	11	816
Ge Zhu China	14	388 1.2×	187 1.2×	155 1.3×	173 1.5×	29 0.3×	34	766
Husain Attarwala United States	11	458 1.4×	131 0.8×	72 0.6×	117 1.0×	90 1.0×	19	760
Annika Frede Germany	13	282 0.9×	186 1.2×	110 0.9×	84 0.7×	35 0.4×	17	611
Dickson Adah China	15	288 0.9×	220 1.4×	76 0.6×	154 1.4×	43 0.5×	22	714
Vincent Holl France	18	373 1.2×	384 2.4×	46 0.4×	107 0.9×	97 1.1×	32	1.0k
Jerry Leung Canada	13	837 2.6×	153 1.0×	132 1.1×	41 0.4×	104 1.2×	23	1.1k
Vicenta Trujillo-Alonso United States	7	182 0.6×	77 0.5×	104 0.9×	116 1.0×	42 0.5×	7	481
Anne Monette Canada	15	496 1.6×	130 0.8×	76 0.6×	94 0.8×	97 1.1×	28	839

Countries citing papers authored by Fu‐Fei Hsu

Since Specialization

Citations

This map shows the geographic impact of Fu‐Fei Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fu‐Fei Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fu‐Fei Hsu more than expected).

Fields of papers citing papers by Fu‐Fei Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fu‐Fei Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fu‐Fei Hsu. The network helps show where Fu‐Fei Hsu may publish in the future.

Co-authorship network of co-authors of Fu‐Fei Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Fu‐Fei Hsu. A scholar is included among the top collaborators of Fu‐Fei Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fu‐Fei Hsu. Fu‐Fei Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Hsu, Fu‐Fei, Hsi‐Chien Huang, Yun‐Chieh Sung, et al.. (2023). A Chemoimmunotherapy Nanogel Enables Efficient Delivery of Interleukin‐2 and Induction of Immunogenic Cell Death for Effective Cancer Therapy. Advanced Functional Materials. 34(1). 9 indexed citations

Lu, Ruei‐Min, Kang-Hao Liang, Hsiao-Ling Chiang, et al.. (2023). Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. Heliyon. 9(5). e15587–e15587. 4 indexed citations

Kumari, Monika, Ruei‐Min Lu, Mu‐Chun Li, et al.. (2022). A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. Journal of Biomedical Science. 29(1). 68–68. 94 indexed citations

Hsu, Fu‐Fei, Kang-Hao Liang, Monika Kumari, et al.. (2022). An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization. International Journal of Pharmaceutics. 627. 122256–122256. 18 indexed citations

Ko, Shih-Han, Chen Wy, Shih-Chieh Su, et al.. (2022). Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants. Journal of Biomedical Science. 29(1). 108–108. 7 indexed citations

Huang, Hsi‐Chien, Yun‐Chieh Sung, Chung‐Pin Li, et al.. (2021). Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours. Gut. 71(9). 1843–1855. 39 indexed citations

Huang, Kuan‐Wei, Fu‐Fei Hsu, Jian‐Tai Qiu, et al.. (2020). Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Science Advances. 6(3). eaax5032–eaax5032. 213 indexed citations

Chiang, Ming‐Tsai, I‐Ming Chen, Fu‐Fei Hsu, et al.. (2020). Gal-1 (Galectin-1) Upregulation Contributes to Abdominal Aortic Aneurysm Progression by Enhancing Vascular Inflammation. Arteriosclerosis Thrombosis and Vascular Biology. 41(1). 331–345. 19 indexed citations

Hsu, Fu‐Fei, Ming‐Tsai Chiang, Fu‐An Li, et al.. (2018). Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation. Oncogene. 38(10). 1688–1701. 31 indexed citations

10.

Hsu, Fu‐Fei, et al.. (2018). Identification of danthron as an isoform-specific inhibitor of HEME OXYGENASE-1/cytochrome P450 reductase interaction with anti-tumor activity. Journal of Biomedical Science. 25(1). 6–6. 8 indexed citations

11.

Liu, Chun‐Hung, Fu‐Fei Hsu, Kuan‐Wei Huang, et al.. (2017). A multifunctional nanocarrier for efficient TRAIL‐based gene therapy against hepatocellular carcinoma with desmoplasia in mice. Hepatology. 67(3). 899–913. 43 indexed citations

12.

Liu, Chun‐Hung, Kun‐Ming Chan, Jiayu Liu, et al.. (2016). Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis. Molecular Pharmaceutics. 13(7). 2253–2262. 31 indexed citations

13.

Ou, Yi-Hung, et al.. (2007). The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. The EMBO Journal. 26(17). 3968–3980. 89 indexed citations

14.

Lee, Ming‐Hui, Chih‐Hsiang Leng, Yuan‐Chih Chang, et al.. (2004). Self-polymerization of archaeal RadA protein into long and fine helical filaments. Biochemical and Biophysical Research Communications. 323(3). 845–851. 16 indexed citations

15.

Lu, Kang, Cheng‐Loong Liang, Han‐Jung Chen, et al.. (2003). Nuclear factor—κB-regulated cyclooxygenase-2 expression in surgery-associated paraspinal muscle injury in rats. Journal of Neurosurgery Spine. 98(2). 181–187. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact